Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information.
Introduction and receptor classification
Serotonin (5-hydroxytryptamine, 5-HT) signals through multiple receptor families. Most are G-protein-coupled receptors; 5-HT3 is a ligand-gated cation channel. Pharmacologic effects depend on receptor subtype and tissue: 5-HT1 receptors generally couple to Gi/o, 5-HT2 to Gq/11, and 5-HT4/6/7 to Gs. Reuptake inhibitors are serotonin modulators but not direct serotonin receptor agonists [1].
Principal agonists
- 5-HT1B/1D agonists: triptans such as sumatriptan and rizatriptan treat selected acute migraine attacks; they inhibit trigeminovascular signaling and can cause cranial vasoconstriction.
- 5-HT1F agonist: lasmiditan treats acute migraine without 5-HT1B-mediated vasoconstriction, but causes CNS effects and driving restrictions.
- 5-HT1A partial agonist: buspirone treats generalized anxiety disorder; onset is gradual, not an immediate panic rescue.
- 5-HT4 agonist: prucalopride promotes intestinal transit and is used in chronic idiopathic constipation in eligible adults [1,2].
Principal antagonists and mixed agents
- 5-HT3 antagonists: ondansetron, granisetron and palonosetron block nausea and vomiting pathways, especially in chemotherapy- and postoperative-related syndromes.
- 5-HT2A antagonism: many second-generation antipsychotics have 5-HT2A antagonism alongside dopamine-receptor actions, but they are not interchangeable selective serotonin antagonists.
- 5-HT2 blockers: cyproheptadine has antihistamine and antiserotonergic activity and may be used in selected cases of serotonin toxicity under expert care.
- Mixed agents: trazodone and mirtazapine modulate serotonergic signaling through several receptor and transporter mechanisms [1].
Important correction: setmelanotide
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist for specific genetic or syndromic obesity indications, not a 5-HT2C serotonin agonist. Older 5-HT2C agonists such as lorcaserin have been withdrawn from the US market; do not present them as routinely available weight-loss medicines [1].
Uses, pharmacokinetics and interactions
Triptans are used for acute migraine, not preventive daily treatment. Sumatriptan has oral, nasal and subcutaneous formulations with route-dependent onset. Ondansetron is metabolized by several CYP enzymes and can prolong QT, particularly with other QT-risk drugs or electrolyte abnormalities. Buspirone is a CYP3A4 substrate and interacts with strong inhibitors and inducers. Prucalopride is predominantly renally eliminated, necessitating review of renal dosing [1,2].
Safety: serotonin toxicity and vascular risk
Serotonin syndrome can occur after combining serotonergic agents such as MAO inhibitors with serotonin reuptake inhibitors, linezolid or certain opioids; findings include autonomic instability, agitation, hyperreflexia and clonus. Triptans are generally contraindicated in certain established vascular diseases and uncontrolled hypertension. Lasmiditan causes sedation/dizziness and requires a product-specific driving restriction. Ondansetron’s QT effects and drug interactions require risk assessment [1].
Clinical pearls
Name the receptor and its functional role, rather than grouping SSRIs, 5-HT3 antagonists and triptans as if they share one mechanism. Serotonin pharmacology is receptor-, tissue- and indication-specific [1].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021–1039. doi:10.1111/head.14153. Available from: https://doi.org/10.1111/head.14153
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.